Literature DB >> 11313923

Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.

D H Kim1, H H Nelson, J K Wiencke, D C Christiani, J C Wain, E J Mark, K T Kelsey.   

Abstract

Death associated protein (DAP)-kinase is a 16 kDa calmodulin-dependent serine/threonine kinase that carries a death domain at its C-terminus. DAP-kinase functions as a positive mediator of apoptosis that is induced by interferon-gamma. Recent studies suggest that DAP-kinase is involved in tumor metastasis and that it can be inactivated by methylation of CpG islands in the promoter region of the gene in some human tumors. However, little is known about the factors that are associated with the occurrence of DAP-kinase promoter methylation. We investigated both the possible associations of tobacco carcinogen and asbestos exposure with DAP-kinase promoter methylation, and the demographic and clinical factors associated with DAP-kinase promoter methylation in non-small cell lung cancer (NSCLC). One hundred and eighty-five patients diagnosed with NSCLC undergoing surgical resection from June, 1992 through December, 1996 at Massachusetts General Hospital participated in this study. Methylation-Specific PCR (MSP), performed using fresh-frozen tissue, was used to determine the methylation status of the promoter region of the DAP-kinase gene. Forty-seven (25%) of 185 tumors showed DAP-kinase promoter methylation. There was a significant association between methylation and an advanced pathologic stage (P=0.003, Fisher's exact test). Methylation of the DAP-kinase promoter was also associated with an increase in tumor size (P=0.009, Fisher's exact test) and lymph node involvement (P=0.04). No association was found between promoter methylation of DAP-kinase and k-ras or p53 mutation. In addition there was no association with a history of exposure to tobacco or asbestos. Controlling for age, sex, and histology, the odds ratios describing the association of DAP-kinase hypermethylation with stage were 2.70 (1.13--6.45), 3.11 (1.37--7.08) and 7.77 (1.21--50.03) in stages II, III and IV, respectively. Stage I cases with DAP-kinase promoter methylation had worse overall survival, but with the small sample size and limited follow-up this did not reach statistical significance. Our findings suggest that methylation of the promoter region of the DAP-kinase gene is not associated with exposure to tobacco or asbestos. However, they strongly suggest that DAP-kinase may be important in the progression of non-small cell lung cancer from early to late stage disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313923     DOI: 10.1038/sj.onc.1204302

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Insights into the role of DNA methylation in disease through the use of mouse models.

Authors:  Melissa Conerly; William M Grady
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

3.  Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.

Authors:  Doerthe Kuester; Altaf A Dar; Christopher C Moskaluk; Sabine Krueger; Frank Meyer; Roland Hartig; Manfred Stolte; Peter Malfertheiner; Hans Lippert; Albert Roessner; Wael El-Rifai; Regine Schneider-Stock
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

Review 4.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

5.  RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation.

Authors:  Bo-Kuan Wu; Szu-Chieh Mei; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating inflammatory gene expression.

Authors:  Rupak Mukhopadhyay; Partho Sarothi Ray; Abul Arif; Anna K Brady; Michael Kinter; Paul L Fox
Journal:  Mol Cell       Date:  2008-11-07       Impact factor: 17.970

Review 7.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

8.  DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.

Authors:  Qinghua Feng; Stephen E Hawes; Joshua E Stern; Linda Wiens; Hiep Lu; Zhao Ming Dong; C Diana Jordan; Nancy B Kiviat; Hubert Vesselle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

9.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.

Authors:  Mingqing Tang; William Xu; Qizhao Wang; Weidong Xiao; Ruian Xu
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

10.  Investigating the epigenetic effects of a prototype smoke-derived carcinogen in human cells.

Authors:  Stella Tommasi; Sang-in Kim; Xueyan Zhong; Xiwei Wu; Gerd P Pfeifer; Ahmad Besaratinia
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.